NASDAQ: OBIO - Orchestra BioMed Holdings, Inc.

Yield per half year: -48.6%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Orchestra BioMed Holdings, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions.

more details
The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2020-08-04
ISIN US68572M1062
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://orchestrabiomed.com
Цена ао 4.38
Change price per day: +3.89% (2.8)
Change price per week: +4.27% (2.79)
Change price per month: -28.7% (4.08)
Change price per 3 month: -44.8% (5.27)
Change price per half year: -48.6% (5.66)
Change price per year: -39.9% (4.84)
Change price per 3 year: -70.7% (9.93)
Change price per year to date: -39.4% (4.8)
All parameters

Underestimation

Title Value Grade
P/S 119.06 1
P/BV 4.83 3
P/E 0 0
EV/EBITDA -5.85 0
Total: 2.88

Efficiency

Title Value Grade
ROA, % -51.59 0
ROE, % -72.19 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0329 10
Total: 9.8

Growth impulse

Title Value Grade
Yield Revenue, % -51.58 0
Yield Ebitda, % 175.37 10
Yield EPS, % 118.86 10
Total: 7.6
More

Institutions Volume Share, %
RTW Investments LP 5620640 15.71
Perceptive Advisors LLC 2432089 6.8
Blackrock Inc. 1468768 4.11
Vanguard Group Inc 1227282 3.43
Price (T.Rowe) Associates Inc 622608 1.74
Geode Capital Management, LLC 425749 1.19
State Street Corporation 285910 0.8
Boxer Capital, LLC 238193 0.67
Charles Schwab Investment Management, Inc. 175545 0.49
Northern Trust Corporation 142879 0.4



Head Job title Payment Year of birth
Mr. David P. Hochman Founder, Chairman of the Board of Directors & CEO 942k 1975 (50 years)
Mr. Darren R. Sherman Founder, President, COO & Director 787k 1971 (54 years)
Mr. Andrew Lawrence Taylor M.B.A. Chief Financial Officer 500.02k 1971 (54 years)
Mr. William Reed Little Executive Vice President of Corporate Development & Strategy N/A 1971 (54 years)
Dr. Yuval Hay Mika D.Sc, Ph.D. GM & CTO of Bioelectronic Therapies N/A 1959 (66 years)
Dr. George Papandreou Ph.D. GM & Senior VP of Focal Therapies N/A 1965 (60 years)
Dr. Hans-Peter Stoll M.D., Ph.D. Chief Clinical Officer N/A
Dr. Avraham Matityahu Fischer M.D. Senior Vice President of Medical Affairs & Innovation N/A 1956 (69 years)
Mr. Bob Laughner Senior Vice President of Regulatory & Quality N/A
Mr. Juan Lorenzo Senior Vice President of Product Development N/A

Address: United States, New Hope. PA, 150 Union Square Drive - open in Google maps, open in Yandex maps
Website: https://orchestrabiomed.com